



OPERATING GRANT PROGRAM Guidelines and Instructions

Effective July 1, 2023 – June 30, 2024

The Leukemia & Lymphoma Society of Canada
2 Lansing Square, Suite 601-2
Toronto, Ontario M2J 4P8
Website: www.bloodcancers.ca

Table of Contents

Key Points.....	Pg 3
Program Description.....	Pg 4
Eligibility.....	Pg 5
Application Process.....	Pg 7
Key Dates.....	Pg 8
Letter of Intent General Information.....	Pg 8
Full Application General Information	Pg 9
Letter of Intent Phase Instructions.....	Pg 11
Full Application Phase Instructions.....	Pg 12
Customer Support Contact Information.....	Pg 16

Key Points

- It is highly recommended to access the LLSC Research Portal, Proposal Central, at <http://proposalcentral.com/> to begin the application process well in advance of any deadlines.
- It is recommended that final submissions at each stage (Letter of Intent/Full Application) be completed prior to the deadline. No aspects of the application will be accepted past the deadline.
- All components of the Application must be present in the order indicated in this document.
- All formatting must adhere to the policy stated in this document.
- The deadlines stated in the Key Dates section are strictly enforced. No exceptions are made to this policy.
- Contact paul.oconnell@lls.org with any questions.

Program Description

The Leukemia & Lymphoma Society of Canada (LLSC) is Canada's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The mission of LLSC is to cure all forms of blood cancer and improve the quality of life of patients and their families. Since its founding in 1955, LLSC has invested millions of dollars for research specifically targeting blood cancers and continues to fund innovative research to advance more breakthrough therapies.

To this end, LLSC also supports community service programs, advocacy, and public and professional education.

LLSC supports research through the Operating Grant (OG) research grant program.

The Operating Grant is a two-year grant designed to provide funding to research that may ultimately lead to a significant change in the understanding, diagnosis, or treatment of leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms.

LLSC will provide funding up to a maximum of \$100,000 per year for two years (up to a maximum total of \$200,000 for the two years). Grant funding will be made in two annual payments.

Partnership Funding Opportunities for 2023

New this year, the LLSC is pleased to announce a research funding partnership with **Cell Therapy Transplant Canada (CTTC)** to fund one (1) grant in this competition. CTTC is a member-led, national, multidisciplinary organization providing leadership and promoting excellence in patient care, research, and education in the field of hematopoietic cell transplant and cell therapy (HCT/CT). CTTC applications should describe an innovative multicentre project that aims to improve the outcome, efficacy, and/or safety of HCT/CT in Canada.

The LLSC is also pleased to announce a research funding partnership with **Myeloma Canada** to fund one (1) grant in this competition. Myeloma Canada is the only national charitable organization created by, and for, Canadians impacted by multiple myeloma. The organization is driven to improve the lives of those affected by myeloma by empowering the community through awareness, education and advocacy programs, and supporting clinical research to find a cure. Since it was founded in 2005, Myeloma Canada has been making myeloma matter. Applications relating to the treatment of multiple myeloma should aim to accelerate the development of Canadian academic cellular therapies.

The LLSC is pleased to partner with the **Cancer Research Society (CRS)** to co-fund ten (10) Operating Grants in this funding cycle. The CRS is a national not-for-profit organization whose sole mission is to fund research on all types of cancer, thereby contributing to the advancement of science aimed at preventing, detecting, and treating the disease.

The LLSC is pleased to announce a research funding partnership with **Waldenstrom's Macroglobulemia Foundation of Canada** to fund one (1) grant in this competition. The Waldenstrom's Macroglobulinemia Foundation of Canada (WMFC) supports Canadians with WM, and their families, by offering a range of services that can enhance quality of life for those with WM and funding research to ultimately discover a cure. WM applications should address signaling, immunology/immunotherapy, tumor microenvironment, "Omics", or IgM Monoclonal Gammopathy of Undetermined Significance (MGUS).

Funds for competitive applications will be awarded on the basis of scientific merit, using a priority rating, and will include evaluation of ethical research. The Scientific Review Panel (SRP) will review all applications. New investigators as well as established ones are encouraged to submit applications.

Eligibility

Researchers in any field are encouraged to apply **but the proposal must directly address blood cancer**.

The Principal Investigator (Applicant) must be based in, or formally affiliated with, a Canadian non-profit Sponsoring Institution at the time funding commences and for the duration of the award. Applicants must hold a primary appointment that permits them to do independent research, supervise students, and publish their findings. Applications from non-academic facilities are not eligible. Applicants should hold a Ph.D., M.D., D.V.M. or equivalent degree.

The Application will require one Principal Investigator (PI) who is responsible for the preparation and submission of the proposal including the budget, the conduct of the research programs and adherence with all stipulations made by LLSC, the LLSC Policies & Procedures document, and the Grant Agreement, if funded. The Principal Investigator must be able to demonstrate a significant track record in the area of hematology and/or blood cancer research.

Investigators must demonstrate that their research environment is equipped and suitable for the proposed study; this includes demonstrated access to patient materials, where applicable. Collaboration between multiple investigators to strengthen the proposed research will be considered favorably, but is not a requirement.

The PI must be an independent investigator, which is defined as a scientist who has dedicated laboratory space, directly hires and supervises laboratory personnel (technicians, graduate students, postdocs and staff scientists), and makes all decisions concerning research activities and use of the grant funds. The PI may not be a trainee or be in a subordinate position (i.e. directed or supervised by another), with respect to the subject matter of the proposed research/activities. Technical support personnel, postdoctoral fellows, research associates,

Adjunct professors, status-only appointments, and investigators working outside of Canada are not permitted to apply as Principal Investigator.

For applicants who do not hold an eligible position, investigators can apply as Principal Investigators if they have a firm offer of an academic position (as described above) at an eligible Host Institution and the appointment is not dependent on the outcome of a pending application. However, the position must start by the grant's start date. In these situations, a letter from an authorized representative of the Host Institution is required, outlining the precise nature of the appointment (including the position title and main tasks), as well as the anticipated start date and duration of the appointment.

“Co-principal investigator” or “co-applicant” refers to a researcher who will be in charge of specific administrative and scientific aspects of the research project, whether or not that researcher has a formal relationship with the Host Institution. Adjunct professors and appointments that are for status only can fall under these categories. These individuals are not eligible to receive grant-funded salary support. Graduate students, postdoctoral fellows, research associates, technical support employees, and investigators working outside of Canada are not included under these categories.

A “collaborator” or “co-investigator” refers to individuals who will make substantial intellectual contributions to the research project or have contributed to the drafting of the application itself, but who are not eligible to be included as “Co-Principal Investigators” or “Co-applicants”. Students, postdoctoral fellows, research associates, lay contributors (including patient partners) and investigators based outside of Canada may be included in this category. Students, postdoctoral fellows and research associates may receive salary support from a grant.

Individuals who have been affected by cancer are considered patient/survivor/caregiver participants/partners. This category may include anyone who is at high risk of cancer, has been diagnosed with cancer, or provides physical and emotional care to someone with cancer but not in a professional or vocational capacity. Patient partners and caregivers can act as “collaborators” or “co-investigators” depending on responsibilities and impact of contribution to the proposed project.

For any questions of eligibility or unusual circumstances not described above, please contact LLSC.

A Principal Investigator may only submit **ONE** Application per application cycle and cannot serve as a Principal Investigator OR Co-Principal Investigator on more than ONE Application per cycle. A Co-Investigator (also known as Collaborator) CAN serve as Co-Investigator on more than one Application. A Principal Investigator or Co-Principal Investigator can serve as a Collaborator on other Applications (See **Definitions** below).

Definitions

Co-Principal Investigators, Co-Investigators, Collaborators, and Key Personnel:

- The Co-Principal Investigator is responsible for developing the Aims of the project.
- The Co-Investigator (who can also be referred to as Collaborator) is responsible for carrying out the Aims of the project.
- A Principal Investigator CANNOT be named as a Principal Investigator or a Co-Principal Investigator on another application during the same application cycle.
- A Principal Investigator can be listed as a Co-Investigator or a Collaborator on other applications in the same cycle, without limit to the number of applications.
- A Collaborator or Co-Investigator can be named on more than one application or funded grant, without limit.
- Patient Partners are patients or caregivers/family members of patients who have direct experience with the disease or intervention being studied but are not participants in the study that may be a part of the research project. Patient Partners can also be collaborators or co-investigators

Application Process

The application process will occur in **two** phases:

- Phase I: Submission and consideration of a Letter of Intent (LOI).
- Phase II: The invitation for and submission of a Full Application.

All application processes, including both the LOI and Full Application submissions, must be made electronically through the LLSC Research Portal, Proposal Central (<https://proposalcentral.com/>). Application templates can be found on this system. Contact paul.oconnell@lls.org with any questions.

Applications will be reviewed via a peer review process by a diverse group of external experts covering the scientific and medical aspects of the review. Final funding recommendations are approved by our independent Medical and Scientific Advisory Committee and Board of Directors.

Only complete applications received by the submission deadline date will be considered. Applications which exceed page limits will not be considered (see **Letter of Intent Phase Instructions** and **Full Application Phase Instructions**).

Key Dates

Phase	Date
Call for Proposals	September 18, 2023
Letter of Intent (LOI) due	October 26, 2023, 4:00 pm (EST)
Notification of Full Application Invite	November 2023
Full application deadline	February 1, 2024, 4:00 pm (EST)
Review Panel Meeting	April 2024
Notification of Awards	May 2024
Award Start Date	July 2024

The submission deadlines will be strictly enforced through Proposal Central, which automatically shuts down submissions after the deadline has passed.

It is highly recommended that submissions are done well before the deadline, as internet traffic may be slow near the deadline, which may result in difficulties in submission. In addition, LLSC's response time to questions may be delayed by the high volume received near the deadline.

Letter of Intent (LOI) General Information

Each Applicant must submit an LOI that includes a lay summary describing the overall proposal organized in the following sections with a total character limit of 4000:

1. Background and Preliminary Data
2. Goals and Objectives
3. Expected Outcomes and Scientific Significance
4. Statement on Patient Partnership and EDI considerations.

The LOI template is found on our grants management website: <https://proposalcentral.com/>

The LOI should provide a brief description of how the goals and/or approaches are novel and innovative, and what impact the research may have on blood cancer. All LOIs will be reviewed, and those judged to be the most promising, competitive and responsive to the goals of the program will be invited to submit a Full Application. The Applicant will be notified via e-mail as to whether or not they have been invited to submit a Full Application. If invited for Full Application submission, the Applicant will immediately have access to the Full Application submission capability in Proposal Central.

Letters of Intent are due **October 26, 2023 at 4:00 PM EST.**

Full Application General Information

The deadline to submit all Full Applications is **February 1, 2024 at 4 PM EST**. Full Applications will only be accepted via (<http://proposalcentral.com/>). The submission deadlines will be strictly enforced.

Please follow character limits and page lengths carefully. Failure to adhere to these instructions will result in administrative disqualification of your application. Contact paul.oconnell@lls.org with any questions.

Full Applications will be reviewed after the **February 1, 2024** submission deadline by a peer review committee composed of a diverse group of external experts (including patient partner representatives). An application that does not meet the program goals, scope or guidelines will be administratively disqualified. Applications will be assigned an initial score by the primary and secondary reviewers. Only applications that initially rank above a scoring level determined by program staff and the committee chair will be discussed in detail for final ranking by the entire committee. Applications will be evaluated for potential significance, novelty, innovation and feasibility. Once ranked by the peer review panel, the highest scoring proposals will be reviewed by the LLSC Scientific Review Panel (SRP). The SRP will identify those proposals to be funded based on scientific merit, responsiveness to programmatic goals and budget availability. Final approval of funding will be made by the appropriate governing boards of the LLSC.

Any Applicant selected for funding will be notified in May 2024 of the funding decision. Please do not call or email LLSC to determine whether the Application has been received, when it will be reviewed or the results of the review. Funding decisions are relayed by email only and are not available by telephone. Applicants can check Proposal Central for the status of their Application.

All priority ranking scores are confidential in that they are available to LLSC's Medical & Scientific Advisory Committee and LLSC's Board of Directors only. Feedback may only be provided for Applications discussed by the full review committee. Written critiques of the Application are not formally provided to Applicants.

Evaluation Criteria

To support the objectives of this funding opportunity, the following evaluation criteria will be used:

Applicant

- Qualifications of the Applicant, including prior research training, experience, and independence (relative to career stage).
- Expertise of the Applicant in the proposed area of research and with the proposed methodology.

Research Approach

- Direct relevance of proposed research to blood cancer.
- Clarity of the research question.
- Completeness of the literature review and relevance to study design/research plan.
- Clarity of rationale for the research approach and methodology.
- Appropriateness of the research design.
- Appropriateness of the research methods.
- Feasibility of the research approach (including recruitment of subjects, project timeline, preliminary data where appropriate, etc.).
- Anticipation of difficulties that may be encountered in the research and mitigation plans for management.
- Inclusion of sex and gender in research design where appropriate.

Originality of the Proposal

- Potential for the creation of new knowledge.
- Originality of the proposed research, in terms of the hypotheses/research questions addressed, novel technology/methodology, and/or novel applications of current technology/methodology.

Impact of the Research

- Research proposed addresses a significant need or gap in the understanding, diagnosis, and/or treatment of blood cancer in Canada.
- Potential for a significant contribution to the improvement of the health of Canadians and/or to the development of more effective health services and products.
- Appropriateness and adequacy of the proposed plan for knowledge dissemination and exchange.

Research Environment

- Suitability of the environment (mentor[s], milieu, and project) to support the Applicant.
- Availability and accessibility of personnel, facilities and infrastructure required to conduct the research.
- Suitability of the environment for the training of personnel.

Patient Partnership

- Is patient partnership integrated into the project?
- Indication of how patient partnership is integrated into the project in a meaningful way
- Indication of how patient partners are recognized and included as members of the project team

EDI considerations

- Is sex, as a biological variable, taken into account in the research design, methods, analysis and interpretation, and/or dissemination of findings?
- Is gender, as a socio-cultural factor, taken into account in the research design, methods, analysis and interpretation, and/or dissemination of findings?
- Are diversity considerations (e.g. conditions, expressions and experiences of different groups identified by age, education, sexual orientation, parental status/responsibility, immigration status, Indigenous status, religion, disability, language, race, place of origin, ethnicity, culture, socio-economic status, and other attributes) taken into account in the research design, methods, analysis and interpretation, and/or dissemination of findings?

Letter of Intent Phase Instructions

Letters of Intent are due **October 26, 2023 at 4PM EST** via Proposal Central (<http://proposalcentral.com/>).

The Applicant should carefully craft the information requested in the LOI as this information will be automatically populated into the Full Application, if approved. The Applicant will be notified by an automated email from Proposal Central stating whether or not the Application has been approved to proceed to the Full Application phase.

The following components comprise the LOI:

- Project Title (75 characters maximum): Provide a title that adheres to the character limit
- Category: New, or resubmission?
- Principal Applicant Information: The Principal Investigator (or PI) is the Applicant
- Institution and Contacts: Please provide the necessary contact information
- Lay summary that includes the Rationale, Objectives, Methodology, Significance, and a statement on Patient Partnership and EDI considerations (4000 characters maximum)
- Keywords

Full Application Phase Instructions

Please follow character limits and page lengths carefully. Failure to adhere to these instructions will result in administrative disqualification of your application. All application processes must be completed using our grants management website (<http://proposalcentral.com/>). Contact paul.oconnell@lls.org with any questions.

Attachments must be submitted in NO smaller than size 12 font, single-spaced, with one-inch margins on letter size (8.5" x 11") paper.

The following components comprise the Full Application:

Project Title (75 characters maximum)

Principal Applicant Information

Institution and contacts

Co-principal investigator (If applicable)

Project Description

- Statement (in layman's terms, not to exceed 1500 characters), for press release.
- Scientific abstract of the proposed research (4500 characters maximum).
- Keywords

Budget Period Details (See Proposal Central form for specific details):

- On these pages, there should be a full listing of funds required, for both year one and year two of funding. The maximum annual total cost cannot exceed \$100,000.00/year. The aggregate cost over 2 years cannot exceed \$200,000.00.
- **Permissible direct costs** include the following:
 - Personnel Expenses including salary, wage, or stipend. **Grants cannot be used to subsidize the salary of the principal investigator(s)**. In total, no more than fifty percent (50%) of the direct costs may be requested for the salary of professional

staff with a post-graduate degree (i.e. M.D., Ph.D., D.V.M.) regardless of function or role, including fringe benefits. This restriction does not apply to technical staff (i.e. lab assistants, nurses, etc.).

- Supplies & Materials requests should be itemized by category.
 - Equipment purchase requests must identify each item of equipment with an acquisition cost of more than \$500.
 - Payment to patient partners with LLSC funds is considered an eligible expense. Please refer to the Policies and Procedures document for more details if the work performed by the patient partner contributes toward the direct costs of the research/activities.
- **Publication Costs:** LLSC permits publication costs as part of the Operating Grant, up to a maximum of \$1500 per year or \$3000 total including applicable taxes.
 - Attach quotations on equipment and services when appropriate.
 - **Impermissible Costs** include patent-related expenses, travel, membership dues, tuition, books and journals.
 - **Indirect Costs:** It is the policy of the LLSC not to fund indirect costs of research. Indirect costs (often referred to as Institutional overhead, IDC, M&A, G&A or pooled costs) are those costs incurred for common or joint objectives that cannot be readily identified with a particular project (general maintenance, utilities, library, etc.).

Budget Summary and Justifications (See Proposal Central form for specific details):

- Attach detailed justification of budget items, including personnel, expendables, equipment, and services (2000 characters maximum for each category).

Organizational Assurances

- Please indicate whether the work involves biohazardous materials, animal experiments or human subjects. Appropriate forms may either be appended to the application or provided once notice of funding is given; the Applicant will have 45 days to provide the appropriate documents once funding has been approved.

Research Proposal

- Description of previous related research in 1 page.

- Description of proposed research in 5 pages (does not include references, figures, or tables). Any relevant figures, references, and tables can be attached as an appendix. The last paragraph of the application should have the heading “**Significance to hematologic malignancy**”. In this section, the Applicant should clearly state how the proposed work addresses the problem of hematologic malignancies.
- Projected timeline (6, 12, 18, 24 months) – 1 page
 - A brief description of the expected progress of the project at the indicated time points.

Patient Partnership Plan

- Maximum 1 page.
- The integration of Patient Partners as part of the project team can help transform research design and execution.
- Provide a patient partnership plan that outlines how the study will embed Patient Partners as part of the research team to ensure the research is aligned with patient partnership principles. Describe how Patient Partners will be engaged at the various stages of the project. This should include:
 - The Patient Partner(s) and/or their communities who will be engaged (e.g., individual Patient Partners, patient advocacy organizations, etc.).
 - Roles and responsibilities of the Patient Partners. (Activities could include protocol design, review of patient-facing materials, clinical trial execution, identification of barriers and opportunities, and knowledge translation.).
 - Inclusion of a patient partner onboarding process and development of Terms of Reference (especially for longer term research programs).
- Suggested references:
 - Canadian Cancer Clinical Trials Network (<https://3ctn.ca/for-researchers/patient-public-involvement/>)
 - Clinical Trials Transformation Initiative (<https://www.ctti-clinicaltrials.org/>)
 - Strategy for Patient-Oriented Research (<https://cihr-irsc.gc.ca/e/45851.html>)
 - Clinical Trials Ontario (<https://www.ctontario.ca/patients-public/resources-for-engaging-patients/>)

EDI consideration letter

- Maximum 1 page.
- Recognizing the variable impacts of cancer on different populations and demographics, LLSC expects that sex, gender and diversity dimensions (plus other intersectionalities (SGBA+)) will be considered in research proposals, analysis and dissemination of results.
- Please provide a response for each question, and we urge the inclusion of these dimensions in your proposal, when applicable.
 - Is sex, as a biological variable, taken into account in the research design, methods, analysis and interpretation, and/or dissemination of findings?
 - Is gender, as a socio-cultural factor, taken into account in the research design, methods, analysis and interpretation, and/or dissemination of findings?
 - Are diversity considerations (e.g. conditions, expressions, and experiences of different groups identified by age, education, sexual orientation, parental status/responsibility, immigration status, Indigenous status, religion, disability, language, race, place of origin, ethnicity, culture, socio-economic status, and other attributes) taken into account in the research design, methods, analysis and interpretation, and/or dissemination of findings?
- Suggested resources:
 - The Principal Applicant is encouraged to complete the sex- and gender- based online training modules through the CIHR Institute of Gender and Health. Please select and complete the training module most applicable to your research project.
 - For additional information on sex, gender and health research, applicants are encouraged to review the “How to integrate sex and gender in research” section on the CIHR website.

Publications

- Selected list of publications in past 5 years (peer reviewed only); with total number of peer reviewed publications (exclude abstracts). Indicate publications where LLSC support has been acknowledged (if any).

Collaboration/Support Letters (Optional)

- When there are significant collaborations, letters of support are helpful. This is particularly important when access to patient samples, animal models, or specialized equipment outside of the Applicant’s laboratory or department is necessary for the proposed research. If a company asset is required and is not commercially available

from scientific supply companies, such as proprietary drugs, a letter from the company supplying this asset should accompany the application. The letters must be signed by an appropriate authority and be on institutional/company letterhead.

Attachments

- Curriculum Vitae (CIHR biosketch format, Principal Applicant and Co-applicant(s))
- Publications
- Research Proposal
- Patient Partnership Plan
- EDI consideration letter
- Relevant figures (Maximum of 5 figures)
- Letter(s) of Collaboration (optional)
- Appropriate forms for Human and Animal Ethics and Biohazards.
- Signature Page (Once all of the mandatory fields are complete, the signature page is available for **e-signing** on Proposal Central and can be **e-signed** by the appropriate person(s)):
 - Signatures of principal Applicant and Co-applicant(s) with dates.
 - Name and signature of head of the department or appropriate academic officer (e.g., Dean or Associate Dean Research), with date.
 - Name and signature of the financial officer, with date.

Customer Support

Please contact:

PROPOSAL CENTRAL Customer Support

By e-mail: pcsupport@altum.com

By phone: +1 800 875 2562 (Toll-free U.S. and Canada) or

+1 703 964 5840 (Direct Dial International)

Normal Business Hours: 8:30am - 5:00pm Eastern Time

(Available Monday through Friday)